Rifampin is the generic equivalent of Rifadin capsules marketed by Sanofi Aventis US and is indicated in the treatment of all forms of tuberculosis and for the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx.
Arthur Bedrosian, president and CEO of Lannett, said: “This approval bolsters our growing portfolio of manufactured pharmaceutical products. We expect to commence marketing both dosages of our Rifampin product in the near term.”